|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study provides evidence that ErbB3 might be a client for Hsp90 in Met-amplified NSCLCs.
|
25117641 |
2014 |
|
HSP90AA1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
|
29247830 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
As an elevated expression of HSP90AA1, HSP90AB1, HSP90B1 and TRAP1 was associated with poorer OS outcomes in patients with NSCLC, these HSP90 members may be potential prognostic biomarkers and drug targets for the treatment of NSCLC.
|
30930968 |
2019 |
|
HSP90AA1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this regard, the present study provides the preclinical basis for a new Hsp90 inhibitor, WK88-1, for the treatment of NSCLCs harboring the T790M mutation in EGFR.
|
24789511 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined treatment of NSCLC cells with sulforaphane plus another HSP90 inhibitor (17-AAG) enhanced the inhibition of EGFR-related signaling both in vitro and in vivo.
|
26036303 |
2015 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the feasibility of <sup>89</sup>Zr-labelled one-armed c-MET antibody onartuzumab PET for detecting relevant changes in c-MET levels induced by c-MET-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib resistance or heat shock protein-90 (HSP90) inhibitor NVP-AUY-922 treatment in human non-small-cell lung cancer (NSCLC) xenografts.
|
28315949 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC.
|
29561705 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this review is to present the data in support of use of HSP90 inhibitors in NSCLC and to provide an overview of the on-going clinical trials involving new-generation HSP90 inhibitors.
|
29521219 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
|
23493311 |
2013 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Eleven Hsp90 inhibitors containing an isoxazolonaphtoquinone core were synthesized and evaluated in two MDR models comprised of sensitive and corresponding resistant cancer cells with P-gp overexpression (human non-small cell lung carcinoma and colorectal adenocarcinoma).
|
31527404 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevated Hsp90 expression has been linked to poor prognosis in patients with non-small cell lung cancer (NSCLC).
|
31802936 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Luminespib (AUY922) is a second-generation heat shock protein 90 (HSP90) inhibitor with demonstrated activity in non-small cell lung cancer (NSCLC).
|
31446981 |
2019 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we evaluated the radiosensitizing effect of the novel Hsp90 inhibitor, NVP-AUY922 (AUY), on NSCLC cell lines harboring EGFR activating mutations and showing acquired resistance to EGFR-TKIs via any of several mechanisms.
|
25607753 |
2015 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that Hsp90 inhibitors may overcome ligand-triggered resistance to new generation ALK inhibitors and may result in more successful treatment of NSCLC patients with EML4-ALK.
|
24952482 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our studies offer a way forward for Hsp90 inhibitors through the rational design of Hsp90 inhibitor combinations that may prevent and/or overcome resistance to Hsp90 inhibitors, providing an effective therapeutic strategy for <i>KRAS</i>-mutant NSCLC.<i></i>.
|
28167505 |
2017 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that N19 may be a potential new-generation TKI or HSP90 inhibitor used for treatment of NSCLC patients who show resistance to current TKI-targeting therapies.
|
27362807 |
2016 |
|
HSP90AA1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The significance of HSP90AA1, HSP90AB1 and HSP90B1 gene polymorphisms in a Turkish population with non-small cell lung cancer.
|
24511009 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we discovered that 2',4'-dimethoxychalcone (1b) disrupted Hsp90 chaperoning function and inhibited the growth of iressa-resistant non-small cell lung cancer (NSCLC, H1975).
|
25855012 |
2015 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
|
30224681 |
2018 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model.
|
25185500 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
KCNQ1OT1 presented a positive correlation with HSP90AA1 which predicted the tumor progression in NSCLC from The Cancer Genome Atlas database.
|
30471108 |
2019 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study investigated the role of Rad51 expression in HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced cytotoxicity in two NSCLC cell lines, A549 and H1975.
|
23069143 |
2012 |
|
HSP90AA1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we report whether Hsp90 inhibitor 17-AAG could enhance salinomycin-induced cytotoxicity in NSCLC cells through modulating TP expression in two non-small-cell lung cancer (NSCLC) cell lines, A549 and H1975.
|
30796972 |
2019 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mechanistically, luteolin induced degradation of the EGF receptor by inhibiting the association of Hsp90 with the mutant EGF receptor, and, therefore, prevented PI3K/Akt/mTOR signalling, which resulted in NSCLC cell apoptosis.
|
24471765 |
2014 |
|
HSP90AA1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We suggest that targeting HSP90 will have clinical impact for NSCLC patients.
|
18320023 |
2008 |